Expression of cancer stem cell markers in basal and penta-negative breast carcinomas - A study of a series of triple-negative tumors

Pathology Research and Practice

Volumn 210, Issue 7, 2014, Pages 432-439

  De Mendonça UchÔa, Diego ^a,b   Graudenz, Marcia Silveira ^a,b   Callegari Jacques, Sidia Maria ^b   Hartmann, Carolina Rigatti ^a   Ferreira, Bruna Pellini ^b   Fitarelli Kiehl, Mariana ^b   Edelweiss, Maria Isabel ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Basal; Breast cancer; CD24; CD44; Triple negative

Indexed keywords

CD24 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; PROTEIN HER1; UNCLASSIFIED DRUG; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BASAL BREAST CARCINOMA; BREAST CARCINOMA; CANCER GRADING; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PENTA NEGATIVE BREAST CARCINOMA; PHENOTYPE; PREVALENCE; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; BASAL CELL CARCINOMA; BIOSYNTHESIS; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TISSUE MICROARRAY;

ADULT; ANTIGENS, CD24; ANTIGENS, CD44; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KERATIN-5; KERATIN-6; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, BASAL CELL; NEOPLASTIC STEM CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901501067     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.03.005     Document Type: Article

References (61)

1. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
2. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10869-10874.
3. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8418-8423.
4. Viale G. Histopathology of primary breast cancer. Breast 2003, 12:391-396.
5. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10:5367-5374.
6. Perou C.M., Jeffrey S.S., van de Rijn M., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9212-9217.
7. Rakha E.A., El-Sayed M.E., Green A.R., et al. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
8. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8:235-244.
9. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
10. Irvin W.J., Carey L.A. What is triple-negative breast cancer?. Eur. J. Cancer 2008, 44:2799-2805.
11. Dawson S.J., Provenzano E., Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer 2009, 45(Suppl. 1):27-40.
12. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948.
13. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
14. Mersin H., Yildirim E., Berberoglu U., et al. The prognostic importance of triple negative breast carcinoma. Breast 2008, 17:341-346.
15. Viale G., Bottiglieri L. Pathological definition of triple negative breast cancer. Eur. J. Cancer 2009, 45(Suppl. 1):5-10.
16. Sasaki Y., Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009, 16:254-259.
17. Billar J.A., Dueck A.C., Stucky C.C., et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann. Surg. Oncol. 2010, 17(Suppl. 3):384-390.
18. Rakha E.A., El-Rehim D.A., Paish C., et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur. J. Cancer 2006, 42:3149-3156.
19. Evans A.J., Rakha E.A., Pinder S.E., et al. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. J. Med. Screen. 2007, 14:210-214.
20. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008, 26:2568-2581.
21. Luck A.A., Evans A.J., Green A.R., et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin. Oncol. (R. Coll. Radiol.) 2008, 20:40-45.
22. Rakha E.A., Tan D.S., Foulkes W.D., et al. Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res. 2007, 9:404. author reply 405.
23. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007, 9:R65.
24. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers?. Int. J. Cancer 2008, 123:236-240.
25. Rakha E.A., Ellis I.O. Triple-negative/basal-like breast cancer: review. Pathology 2009, 41:40-47.
26. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 2009, 15:2302-2310.
27. Lerma E., Barnadas A., Prat J. Triple negative breast carcinomas: similarities and differences with basal like carcinomas. Appl. Immunohistochem. Mol. Morphol. 2009, 17:483-494.
28. Nofech-Mozes S., Trudeau M., Kahn H.K., et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res. Treat. 2009, 118:131-137.
29. Kuroda N., Ohara M., Inoue K., et al. The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med. Mol. Morphol. 2009, 42:128-131.
30. Thike A.A., Cheok P.Y., Jara-Lazaro A.R., et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod. Pathol. 2010, 23:123-133.
31. Badve S., Dabbs D.J., Schnitt S.J., et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011, 24:157-167.
32. Rakha E.A., El-Sayed M.E., Reis-Filho J., et al. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res. Treat. 2009, 113:411-422.
33. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14:1368-1376.
34. Liu Z.B., Wu J., Ping B., et al. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype. Tumor 2009, 95:53-62.
35. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 2010, 7:e1000279.
36. Ponti D., Zaffaroni N., Capelli C., et al. Breast cancer stem cells: an overview. Eur. J. Cancer 2006, 42:1219-1224.
37. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N. Engl. J. Med. 2006, 355:1253-1261.
38. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 2007, 356:217-226.
39. Cariati M., Purushotham A.D. Stem cells and breast cancer. Histopathology 2008, 52:99-107.
40. Morrison B.J., Schmidt C.W., Lakhani S.R., et al. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res. 2008, 10:210.
41. Kai K., Arima Y., Kamiya T., et al. Breast cancer stem cells. Breast Cancer 2009, 17:80-85.
42. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
43. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006, 8:R59.
44. + tumor cells in invasive breast carcinomas. Hum. Pathol. 2008, 39:1096-1102.
45. - phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med. Oncol. 2011, 28:745-752.
46. Kim H.J., Kim M.J., Ahn S.H., et al. Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 2011, 20:78-85.
47. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008, 10:R53.
48. Ricardo S., Vieira A.F., Gerhard R., et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 2011, 64:937-946.
49. Idowu M.O., Kmieciak M., Dumur C., et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 2012, 43:364-373.
50. Ahmed M.A., Aleskandarany M.A., Rakha E.A., et al. A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res. Treat. 2012, 133:979-995.
51. Abramson J.H. WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol. Perspect. Innov. 2011, 8:1.
52. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
53. Conforti R., Boulet T., Tomasic G., et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann. Oncol. 2007, 18:1477-1483.
54. Tischkowitz M., Brunet J.S., Begin L.R., et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7:134.
55. Sutton L.M., Han J.S., Molberg K.H., et al. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am. J. Clin. Pathol. 2010, 134:782-787.
56. Thike A.A., Iqbal J., Cheok P.Y., et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am. J. Surg. Pathol. 2010, 34:956-964.
57. Bernardi M.A., Logullo A.F., Pasini F.S., et al. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Oncol. Rep. 2012, 27:28-38.
58. Park S.Y., Lee H.E., Li H., et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res. 2010, 16:876-887.
59. Lyzak J.S., Yaremko M.L., Recant W., et al. Role of CD44 in nonpalpable T1a and T1b breast cancer. Hum. Pathol. 1997, 28:772-778.
60. Aigner S., Ramos C.L., Hafezi-Moghadam A., et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J. 1998, 12:1241-1251.
61. Kristiansen G., Machado E., Bretz N., et al. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab. Invest. 2010, 90:1102-1116.